Stock listing

LS Exchange:A1JJA3 Insmed Incorporated Aktie

German listing (LS Exchange) of Insmed Incorporated · home listing NASDAQ:INSM

Follow Insmed Incorporated into a list and get an email when it puts out news.

Home listing price · NASDAQ:INSM

$95.29 USD -0.98 (-1.0%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:INSM

Since Jul 6, 2026 -14.6% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$94.38 – $97.88 USDOct 19, 2026
Volume
2.72M sharesOct 19, 2026
Market value
$20.81B USDAt the close on Oct 19, 2026 · price × 218.4M shares outstanding
Insmed Incorporated logo
Ticker
LS Exchange:A1JJA3
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Calls

Replays

  • Insmed (NASDAQ:INSM) Q2 2026 Earnings Call

    Thu, Aug 06, 2026 · 8:00 AM ET

    Watch Transcript

  • Insmed (NASDAQ:INSM) Q1 2026 Earnings Call

    Thu, May 07, 2026 · 8:00 AM ET

    Watch Transcript

  • Insmed (NASDAQ:INSM) Q4 2025 Earnings Call

    Thu, Feb 19, 2026 · 8:00 AM ET

    Watch Transcript

Latest news

Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan

Oct 19, 2026

Insmed Features the Global Phase 3 PALM Clinical Development Program Evaluating Treprostinil Palmitil Inhalation Powder (TPIP) at CHEST 2026

Oct 15, 2026

Insmed to Present New Data Across Its Respiratory Portfolio at CHEST 2026 and IDWeek 2026

Oct 14, 2026

Insmed Announces CFO Transition

Oct 5, 2026

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

Sep 21, 2026

Insmed Expands Community Impact During Fifth Annual Global Day of Good

Sep 16, 2026

Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026

Sep 3, 2026

Insmed to Present at September 2026 Investor Conferences

Aug 26, 2026

BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Aug 24, 2026

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

Aug 6, 2026

All Insmed Incorporated news

Decks

Insmed Incorporated on 6ix

Sector
Health care
Industry
Biotechnology
News releases
36 in the last 12 months · 208 in all · newest Oct 19, 2026 · oldest 2019
Calls
22 calls with a replay · 22 with a transcript · latest Aug 6, 2026
Decks
46 decks · latest Aug 6, 2026

Where Insmed Incorporated is listed

ListingExchangeCountryCurrency
NASDAQ:INSM · Home listingNASDAQUnited StatesUSD
gettex:IM8NgettexGermanyEUR
Tradegate:IM8NTradegateGermanyEUR
LSE:0JAVLSEUnited KingdomUSD
LS Exchange:A1JJA3 · This pageLS ExchangeGermanyEUR
BMV:INSMBMVMexicoMXN
BOATS:INSMBOATSUnited StatesUSD
Lang & Schwarz:A1JJA3Lang & SchwarzGermanyEUR
Milan:1INSMMilanItalyEUR
Stuttgart:IM8NStuttgartGermanyEUR
BIVA:INSMBIVAMexicoMXN
Frankfurt:IM8NFrankfurtGermanyEUR
BX Swiss:IM8NBX SwissSwitzerlandCHF
Hamburg:IM8NHamburgGermanyEUR
Dusseldorf:IM8NDusseldorfGermanyEUR
Hanover:IM8NHanoverGermanyEUR
Xetra:IM8NXetraGermanyEUR

Log in to ask 6ix AI your own questions about Insmed Incorporated.